Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update
LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.
洛杉磯，2024年10月30日/美通社/--Aadi生命科學公司（納斯達克：AADI）今日宣佈將於2024年11月6日星期三報告2024年第三季度財務業績，並提供最新的公司更新。這些結果將在Aadi生命科學網站的「投資者與資訊」頁面（aadibio.com）上提供。
About Aadi Bioscience
關於Aadi生命科學
Aadi is a precision oncology company focused on the commercialization of FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at and connect with us on Twitter and LinkedIn.
Aadi是一家專注於FYARRO商品化的精準腫瘤學公司，用於治療局部晚期無法手術切除或轉移性惡性血管周細胞瘤（PEComa）的成人患者。有關公司的更多信息，請訪問Aadi網站，並在Twitter和LinkedIn上關注我們。
Contact:
[email protected]
聯繫方式：
[email protected]
SOURCE Aadi Bioscience
來源：Aadi生命科學
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
